Skip to main content

Table 8 Estimated market share (%) of biologic agents for the treatment of moderate to severe psoriasis

From: Budget impact analysis of ustekinumab in the management of moderate to severe psoriasis in Greece

Agent Base year Year 1 Year 2 Year 3 Year 4 Year 5
Adalimumab 30 27 25 24 23 23
Etanercept 45 42 39 37 36 35
Infliximab 25 22 20 18 17 16
Ustekinumab 0 9 16 21 24 26